# Hongming Pan

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/hongming-pan/

## Facts

| Field | Value |
| --- | --- |
| Citations | 23,004 |
| Field | Cancer Immunotherapy and Biomarkers |
| h-index | 62 |
| i10-index | 187 |
| Last Known Institution | Sir Run Run Shaw Hospital |
| OpenAlex ID | https://openalex.org/A5045553246 |
| ORCID iD | https://orcid.org/0000-0001-5034-3392 |
| Works | 364 |

## Researcher papers

- [Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/regorafenib-plus-best-supportive-care-versus-placebo-plus-best-supportive-care/)
- [Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial](https://scholariq.org/papers/linifanib-versus-sorafenib-in-patients-with-advanced-hepatocellular-carcinoma/)
- [Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial](https://scholariq.org/papers/toripalimab-plus-chemotherapy-in-treatment-naive-advanced-esophageal-squamous/)
- [BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non–Small-Cell Lung Cancer](https://scholariq.org/papers/beyond-a-randomized-double-blind-placebo-controlled-multicenter-phase-iii-study/)
- [Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer](https://scholariq.org/papers/sintilimab-plus-chemotherapy-for-unresectable-gastric-or-gastroesophageal/)
- [Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial](https://scholariq.org/papers/intercalated-combination-of-chemotherapy-and-erlotinib-for-patients-with/)
- [Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial](https://scholariq.org/papers/tepotinib-plus-gefitinib-in-patients-with-egfr-mutant-non-small-cell-lung-cancer/)
- [Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial](https://scholariq.org/papers/safety-efficacy-and-pharmacokinetics-of-almonertinib-hs-10296-in-pretreated/)
- [Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial](https://scholariq.org/papers/efficacy-of-aumolertinib-hs-10296-in-patients-with-advanced-egfr-t790m-nsclc/)

## Researcher topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Gastric Cancer Management and Outcomes](https://scholariq.org/topics/gastric-cancer-management-and-outcomes/)
- [Hepatocellular Carcinoma Treatment and Prognosis](https://scholariq.org/topics/hepatocellular-carcinoma-treatment-and-prognosis/)

## Researcher university

- [Sir Run Run Shaw Hospital](https://scholariq.org/institutions/sir-run-run-shaw-hospital/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.